Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
Last trade$0.3397
Day change-$0.066 (-16.27%)
Day range$0.32 – $0.396
Volume194,521
Market cap$0M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$248.32K
Price / earnings
—
Price / book
0.03×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.2×
Profitability
Earnings per share
-$42.48
Return on assets
-89.06%
Return on equity
-330.06%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.39×
Current ratio
0.02×
Quick ratio
0.02×
Cash ratio
0.02×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.1M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PFSA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Revenue
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
Selling, general and administrative
$4.63M
$1.72M
$2.86M
$2.32M
$20.99M
Research and development
$222K
$823K
$1.15M
$1.26M
$722K
Total operating expenses
$4.85M
$2.55M
$4.01M
$3.57M
$21.71M
Operating income
-$4.85M
-$2.55M
-$4.01M
-$3.57M
-$21.71M
Interest expense
-$25K
-$2.43M
-$78K
-$2.6M
-$1.61M
Income before taxes
-$4.95M
-$8.76M
-$3.46M
-$8.57M
-$26.09M
Income taxes
$0
$0
$0
$0
$0
Net income
-$4.95M
-$8.76M
-$3.46M
-$8.57M
-$26.09M
Net income attributable to common shareholders
-$4.95M
-$8.76M
-$3.46M
-$8.57M
-$26.09M
EBITDA
-$4.85M
-$2.54M
-$4.01M
-$3.57M
-$21.71M
Basic earnings per share
-$6.23
-$151.80
-$2.05
—
-$6,167.85
Diluted earnings per share
-$6.23
-$151.80
-$2.05
—
-$6,167.85
Recent news
Company coverage with links to the original publishers.
Profusa has submitted a comprehensive response package to its European Notified Body GMED following successful completion of Stage 1 and Stage 2 assessments for CE Mark certification of its Lumee Oxygen Platform. The submission includes updates to technical documentation, quality system evidence, clinical evaluation activities, and validation information. The company remains committed to obtaining CE Mark certification to support European commercialization of its tissue oxygen monitoring technology.
Profusa, Inc. (PFSA) has been granted approval by the Nasdaq Hearings Panel to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market. The company must satisfy interim milestones and comply with bid price and stockholders' equity requirements by July 6, 2026, to maintain its continued listing.
Profusa (NASDAQ: PFSA) shares plummeted 40.27% on Tuesday following the announcement of a Letter of Intent to acquire BioInsights' PanOmics multi-omics diagnostics platform for approximately $30 million in an all-equity deal. The acquisition marks Profusa's strategic expansion into molecular diagnostics and aims to complement its Lumee real-time biochemistry monitoring system, with initial commercialization targeting pancreatic cancer.
Profusa announced an all-equity acquisition of BioInsights LLC's PanOmics multi-omics diagnostics platform, expanding into precision diagnostics. The deal adds $30 million to shareholder equity and accelerates commercialization through integration with Profusa's Lumee platform. The company is also advancing a Mayo Clinic collaboration for pancreatic cancer applications. Profusa shares surged 134.99% in premarket trading.
Profusa announced a new distributor partnership with MedSell in France to commercialize its Lumee Oxygen tissue monitoring device for critical limb threatening ischemia (CLTI) patients. This partnership, combined with existing distributors across Europe, now covers approximately 200,000 annual CLI cases in the EU. The company projects $0.5-$2 million revenue in 2026 and $9-$13 million in 2027, with plans to reach $200-$250 million by 2030.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.